To develop and commercialize new nanomedicines for chronic diseases NMC integrates
- Small companies and academic researchers
- Pre-clinical and clinical product development
- Basic and applied research in chemistry, biology and medicine
- Biotechnology (BT) and information technology (IT)
The NanoMedicine Cluster (formerly known as the Vaccine Therapy Cluster) is built around a
novel topical DermaVir Patch nanomedicine platform technology. It has been transferred from the USA to Hungary
to further optimize the technology and to develop new nanomedicines for HIV/AIDS, allergy and atherosclerosis.
The partners of Hungarian NMC are innovative biotech companies and experts from universities, hospitals and
academic institutions. The activities of the Hungarian partners are enhanced by foreign collaborators from
biotech companies, hospitals, institutions, universities specialized in different fields like clinical trials,
regulatory affairs, intellectual properties, basic and clinical immunology, data management, ISO quality
management and much more. Genetic Immunity has provided the core nanomedicine platform technology through its Hungarian
I want to say how we are grateful…Much Appreciated …Many Thanks…from the deep of my heart.
Richmond locksmith companies
Cuyahoga Falls OH locksmiths
locksmiths Santa Clarita CA
locksmiths Apple Valley CA
locksmith companies Lake Charles
find a locksmith
Your Key Locksmith
founder, Prof. Julianna Lisziewicz. Prof. Lisziewicz has been leading the DermaVir Patch development from the
concept to the clinic and she has been taken the responsibility to coordinate the scientific and business
activities of the NMC. The market-oriented activities of the cluster presently target product development for
unmet medical needs like HIV/AIDS, atherosclerosis, allergy. NMC is an open cluster and will expand to develop
effective medicines for the treatment of emerging infectious diseases and cancers. The ambitious goal of
Genetic Immunity, the core company in the NMC, is to bring the first nanomdeicine therapy against HIV/AIDS to
the market and become a globally competitive player in the new nanomedicine biopharmaceutical industry.
Genetic Immunity's first topical nanomedicine product, the DermaVir Patch, is presently under clinical
evaluation in the USA and EU.
*Formerly known as the Vacine Therapy Cluster (VTC)